Rash News and Research

RSS

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

2 Sep 2026

Genetic marker links popular seizure drug to life-threatening reaction

A genetic marker already used to flag risk of a life-threatening reaction to the antibiotic vancomycin also identifies patients at risk of that reaction to lamotrigine - and it is missing from the gene panels clinicians order before prescribing the drug, Vanderbilt Health-led researchers report Sept. 2 in JAMA Network Open.

2 Sep 2026

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

From Dana-Farber Cancer Institute, Inc. 29 Aug 2026

Freshwater swimming linked to doubled risk of skin problems and stomach bugs

People swimming in rivers and lakes could be putting themselves at risk of nasty skin conditions and stomach bugs, according to a new study from the University of East Anglia.

27 Aug 2026

FDA approves first RAS-targeted therapy for metastatic pancreatic cancer

27 Aug 2026

New drug delivers promising survival gains in pancreatic cancer

About 90% of people with pancreatic cancer have pancreatic ductal adenocarcinoma (PDAC), which is driven by an activating mutation in the KRAS gene.

9 Aug 2026

People with eczema face higher risk of developing shingles

An analysis in JDDG: Journal der Deutschen Dermatologischen Gesellschaft found that people with eczema (also known as atopic dermatitis) face an elevated risk of developing shingles (or herpes zoster).

5 Aug 2026

Review highlights traditional Chinese medicine for Chikungunya fever management

Chikungunya fever, caused by Chikungunya virus (CHIKV), has re‑emerged as a major global health threat. The 2025 outbreak in Guangdong, China – the largest local epidemic ever recorded – marks a critical epidemiological turning point.

9 Jul 2026

Varicella-zoster virus inflicts lasting damage to nerves and the brain, study reveals

For millions worldwide, herpes zoster pain does not end when the rash fades. Postherpetic neuralgia can last for years or even a lifetime, devastating quality of life.

26 Jun 2026

New project launches to advance chikungunya vaccine in Africa

Funded by the Global Health EDCTP3 Joint Undertaking, a new €15.3 million project coordinated by Institut Pasteur brings together seven partners across four continents to advance clinical trials and prepare for the manufacturing of a chikungunya vaccine in Africa.

8 Jun 2026

Daraxonrasib significantly extends survival in metastatic pancreatic cancer

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

31 May 2026

Climate change could expand chikungunya into temperate regions worldwide

Chikungunya ('to become contorted' in the Kimakonde language, named after the characteristic joint ache) is classified as one of the neglected tropical diseases by the World Health Organization.

27 May 2026

Health experts outline symptoms and risks of shipboard hantavirus

It's one of the cruisegoer's biggest fears: a contagious disease outbreak at sea.

18 May 2026

Global collaboration can improve diagnosis and care for children with Kawasaki disease

International collaboration in research, diagnosis and care is critical to reducing the risk of serious heart conditions for children with Kawasaki disease worldwide, according to a new science advisory published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

18 May 2026

Asymptomatic transmission plays a prominent role in mpox infection patterns

A Kaiser Permanente study of nearly 8,000 men shows that in mid- to late 2024, mpox was far more common among men who have sex with men than previously thought. Individuals without symptoms accounted for most infections and likely played a prominent role in transmission, contrary to prior assumptions that people had to be symptomatic to spread the disease.

15 May 2026

Targeted RAS inhibitor shows promise against pancreatic cancer mutations

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

7 May 2026

Using Apple Watch and AI to protect children undergoing cancer treatment from infections

A new trial will test whether a tool that harnesses Apple Watch health data and artificial intelligence can help protect children undergoing cancer treatment from infections.

6 May 2026

Injectable immunotherapy shrinks precancerous oral lesions in clinical trial

Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

21 Apr 2026

New monoclonal antibody shows promise for preventing Lyme disease

A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data presented by Mark Klempner, MD, at the World Vaccine Congress 2026 in Washington D.C.

8 Apr 2026

COCOON trial protocol halves skin toxicities in lung cancer treatment

A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled "Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC."

3 Apr 2026